全文获取类型
收费全文 | 5573篇 |
免费 | 441篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 31篇 |
儿科学 | 260篇 |
妇产科学 | 219篇 |
基础医学 | 712篇 |
口腔科学 | 36篇 |
临床医学 | 596篇 |
内科学 | 1157篇 |
皮肤病学 | 100篇 |
神经病学 | 610篇 |
特种医学 | 109篇 |
外科学 | 526篇 |
综合类 | 59篇 |
一般理论 | 6篇 |
预防医学 | 742篇 |
眼科学 | 50篇 |
药学 | 380篇 |
中国医学 | 16篇 |
肿瘤学 | 418篇 |
出版年
2023年 | 33篇 |
2022年 | 23篇 |
2021年 | 115篇 |
2020年 | 97篇 |
2019年 | 119篇 |
2018年 | 155篇 |
2017年 | 92篇 |
2016年 | 138篇 |
2015年 | 140篇 |
2014年 | 200篇 |
2013年 | 310篇 |
2012年 | 421篇 |
2011年 | 478篇 |
2010年 | 246篇 |
2009年 | 209篇 |
2008年 | 330篇 |
2007年 | 347篇 |
2006年 | 355篇 |
2005年 | 356篇 |
2004年 | 320篇 |
2003年 | 307篇 |
2002年 | 297篇 |
2001年 | 63篇 |
2000年 | 33篇 |
1999年 | 44篇 |
1998年 | 53篇 |
1997年 | 30篇 |
1996年 | 37篇 |
1995年 | 37篇 |
1994年 | 26篇 |
1993年 | 37篇 |
1992年 | 32篇 |
1991年 | 20篇 |
1990年 | 28篇 |
1989年 | 29篇 |
1988年 | 22篇 |
1987年 | 25篇 |
1986年 | 25篇 |
1985年 | 21篇 |
1984年 | 26篇 |
1983年 | 28篇 |
1982年 | 35篇 |
1981年 | 26篇 |
1980年 | 24篇 |
1978年 | 14篇 |
1977年 | 23篇 |
1975年 | 13篇 |
1974年 | 16篇 |
1973年 | 17篇 |
1972年 | 15篇 |
排序方式: 共有6027条查询结果,搜索用时 15 毫秒
1.
2.
Cheryl L. Rock PhD RD Cynthia A. Thomson PhD RD Kristen R. Sullivan MS MPH Carol L. Howe MD MLS Lawrence H. Kushi ScD Bette J. Caan DrPH Marian L. Neuhouser PhD RD Elisa V. Bandera MD PhD Ying Wang PhD Kimberly Robien PhD RD Karen M. Basen-Engquist PhD MPH Justin C. Brown PhD Kerry S. Courneya PhD Tracy E. Crane PhD RDN David O. Garcia PhD FACSM Barbara L. Grant MS RDN CSO FAND Kathryn K. Hamilton MA RDN CSO CDN FAND Sheri J. Hartman PhD Stacey A. Kenfield ScD Maria Elena Martinez PhD Jeffrey A. Meyerhardt MD MPH Larissa Nekhlyudov MD MPH Linda Overholser MD Alpa V. Patel PhD Bernardine M. Pinto PhD Mary E. Platek PhD RD CDN Erika Rees-Punia PhD MPH Colleen K. Spees PhD MEd RD LD FAND Susan M. Gapstur PhD Marjorie L. McCullough ScD RD 《CA: a cancer journal for clinicians》2022,72(3):230-262
The overall 5-year relative survival rate for all cancers combined is now 68%, and there are over 16.9 million survivors in the United States. Evidence from laboratory and observational studies suggests that factors such as diet, physical activity, and obesity may affect risk for recurrence and overall survival after a cancer diagnosis. The purpose of this American Cancer Society guideline is to provide evidence-based, cancer-specific recommendations for anthropometric parameters, physical activity, diet, and alcohol intake for reducing recurrence and cancer-specific and overall mortality. The audiences for this guideline are health care providers caring for cancer survivors as well as cancer survivors and their families. The guideline is intended to serve as a resource for informing American Cancer Society programs, health policy, and the media. Sources of evidence that form the basis of this guideline are systematic literature reviews, meta-analyses, pooled analyses of cohort studies, and large randomized clinical trials published since 2012. Recommendations for nutrition and physical activity during cancer treatment, informed by current practice, large cancer care organizations, and reviews of other expert bodies, are also presented. To provide additional context for the guidelines, the authors also include information on the relationship between health-related behaviors and comorbidities, long-term sequelae and patient-reported outcomes, and health disparities, with attention to enabling survivors' ability to adhere to recommendations. Approaches to meet survivors' needs are addressed as well as clinical care coordination and resources for nutrition and physical activity counseling after a cancer diagnosis. 相似文献
3.
Kerryn W. Reding Aaron K. Aragaki Richard K. Cheng Ana Barac Sylvia Wassertheil-Smoller Jessica Chubak Marian C. Limacher W. Gregory Hundley Ralph D'Agostino Jr. Mara Z. Vitolins Theodore M. Brasky Laurel A. Habel Eric J. Chow Rebecca D. Jackson Chu Chen April Morgenroth Wendy E. Barrington Matthew Banegas Matthew Barnhart Rowan T. Chlebowski 《The oncologist》2020,25(8):712-721
4.
5.
6.
7.
8.
Deborah N. N. Lo‐Fo‐Wong Hanneke C. J. M. de Haes Neil K. Aaronson Doris L. van Abbema Mathilda D. den Boer Marjan van Hezewijk Marcelle Immink Ad A. Kaptein Marian B. E. Menke‐Pluijmers Anna K. L. Reyners Nicola S. Russell Manon Schriek Sieta Sijtsema Geertjan van Tienhoven Mathilde G. E. Verdam Mirjam A. G. Sprangers 《Psycho-oncology》2020,29(3):539-549
9.
Agnes G Schuurman Dorina M van der Kolk Marian A Verkerk Erwin Birnie Adelita V Ranchor Mirjam Plantinga Irene M van Langen 《European journal of human genetics : EJHG》2015,23(9):1124-1128
We explored the dilemma between patients'' right not to know their genetic status and the efficient use of health-care resources in the form of clinical cancer screening programmes. Currently, in the Netherlands, 50% risk carriers of heritable cancer syndromes who choose not to know their genetic status have access to the same screening programmes as proven mutation carriers. This implies an inefficient use of health-care resources, because half of this group will not carry the familial mutation. At the moment, only a small number of patients are involved; however, the expanding possibilities for genetic risk profiling means this issue must be addressed because of potentially adverse societal and financial impact. The trade-off between patients'' right not to know their genetic status and efficient use of health-care resources was discussed in six focus groups with health-care professionals and patients from three Dutch university hospitals. Professionals prefer patients to undergo a predictive DNA test as a prerequisite for entering cancer screening programmes. Professionals prioritise treating sick patients or proven mutation carriers over screening untested individuals. Participation in cancer screening programmes without prior DNA testing is, however, supported by most professionals, as testing is usually delayed and relatively few patients are involved at present. Reducing the number of 50% risk carriers undergoing screening is expected to be achieved by: offering more psychosocial support, explaining the iatrogenic risks of cancer screening, increasing out-of-pocket costs, and offering a less stringent screening programme for 50% risk carriers. 相似文献
10.